vs
Side-by-side financial comparison of Nutex Health, Inc. (NUTX) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $151.7M, roughly 1.2× Nutex Health, Inc.). Nutex Health, Inc. runs the higher net margin — 7.8% vs 1.6%, a 6.2% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -41.1%). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs -0.2%).
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
NUTX vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $151.7M | $177.4M |
| Net Profit | $11.8M | $2.9M |
| Gross Margin | 30.4% | — |
| Operating Margin | 20.4% | 3.9% |
| Net Margin | 7.8% | 1.6% |
| Revenue YoY | -41.1% | 5.0% |
| Net Profit YoY | -80.8% | — |
| EPS (diluted) | $2.34 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $151.7M | $196.9M | ||
| Q3 25 | $267.8M | $179.5M | ||
| Q2 25 | $244.0M | $181.1M | ||
| Q1 25 | $211.8M | $168.9M | ||
| Q4 24 | $257.6M | $187.3M | ||
| Q3 24 | $78.8M | $168.6M | ||
| Q2 24 | $76.1M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $11.8M | — | ||
| Q3 25 | $55.4M | $5.4M | ||
| Q2 25 | $-17.7M | $-4.8M | ||
| Q1 25 | $21.2M | $4.8M | ||
| Q4 24 | $61.6M | — | ||
| Q3 24 | $-8.8M | $-143.5M | ||
| Q2 24 | $-364.0K | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 30.4% | 79.5% | ||
| Q3 25 | 57.8% | 80.9% | ||
| Q2 25 | 51.2% | 77.4% | ||
| Q1 25 | 55.9% | 79.7% | ||
| Q4 24 | 55.0% | 78.7% | ||
| Q3 24 | 27.8% | 76.9% | ||
| Q2 24 | 29.7% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 20.4% | 1.2% | ||
| Q3 25 | 48.7% | 3.5% | ||
| Q2 25 | 13.8% | 4.7% | ||
| Q1 25 | 38.1% | 1.2% | ||
| Q4 24 | 44.4% | 13.2% | ||
| Q3 24 | 12.3% | -82.8% | ||
| Q2 24 | 7.0% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 7.8% | — | ||
| Q3 25 | 20.7% | 3.0% | ||
| Q2 25 | -7.3% | -2.7% | ||
| Q1 25 | 10.0% | 2.8% | ||
| Q4 24 | 23.9% | — | ||
| Q3 24 | -11.2% | -85.1% | ||
| Q2 24 | -0.5% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $2.34 | $0.05 | ||
| Q3 25 | $7.76 | $0.12 | ||
| Q2 25 | $-2.95 | $-0.11 | ||
| Q1 25 | $3.33 | $0.10 | ||
| Q4 24 | $11.56 | $0.38 | ||
| Q3 24 | $-1.72 | $-3.11 | ||
| Q2 24 | $-0.07 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $185.6M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $329.4M | $653.9M |
| Total Assets | $918.5M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $185.6M | $238.4M | ||
| Q3 25 | $166.0M | $246.3M | ||
| Q2 25 | $96.7M | $445.9M | ||
| Q1 25 | $84.7M | $493.6M | ||
| Q4 24 | $40.6M | $484.6M | ||
| Q3 24 | $46.9M | $453.8M | ||
| Q2 24 | $40.8M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $329.4M | $693.1M | ||
| Q3 25 | $317.2M | $727.2M | ||
| Q2 25 | $235.3M | $757.8M | ||
| Q1 25 | $176.9M | $798.5M | ||
| Q4 24 | $132.4M | $778.3M | ||
| Q3 24 | $60.4M | $749.6M | ||
| Q2 24 | $62.7M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $918.5M | $1.3B | ||
| Q3 25 | $964.5M | $1.3B | ||
| Q2 25 | $841.0M | $1.5B | ||
| Q1 25 | $761.9M | $1.6B | ||
| Q4 24 | $655.3M | $1.6B | ||
| Q3 24 | $438.5M | $1.5B | ||
| Q2 24 | $422.4M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $70.4M | — |
| Free Cash FlowOCF − Capex | $69.0M | — |
| FCF MarginFCF / Revenue | 45.5% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | 5.95× | — |
| TTM Free Cash FlowTrailing 4 quarters | $245.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $70.4M | $43.7M | ||
| Q3 25 | $99.5M | $60.8M | ||
| Q2 25 | $27.3M | $12.0M | ||
| Q1 25 | $51.0M | $35.5M | ||
| Q4 24 | $54.0K | $33.1M | ||
| Q3 24 | $6.8M | $53.9M | ||
| Q2 24 | $13.3M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $69.0M | $43.5M | ||
| Q3 25 | $99.2M | $57.0M | ||
| Q2 25 | $26.5M | $9.3M | ||
| Q1 25 | $50.9M | $26.9M | ||
| Q4 24 | $-341.0K | $31.0M | ||
| Q3 24 | $6.2M | $49.8M | ||
| Q2 24 | $12.7M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 45.5% | 22.1% | ||
| Q3 25 | 37.0% | 31.7% | ||
| Q2 25 | 10.9% | 5.1% | ||
| Q1 25 | 24.0% | 15.9% | ||
| Q4 24 | -0.1% | 16.6% | ||
| Q3 24 | 7.8% | 29.6% | ||
| Q2 24 | 16.7% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.9% | 0.1% | ||
| Q3 25 | 0.1% | 2.2% | ||
| Q2 25 | 0.3% | 1.5% | ||
| Q1 25 | 0.0% | 5.1% | ||
| Q4 24 | 0.2% | 1.1% | ||
| Q3 24 | 0.8% | 2.4% | ||
| Q2 24 | 0.7% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 5.95× | — | ||
| Q3 25 | 1.80× | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.40× | 7.37× | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
